Researchers are rediscovering the awesome power of psychedelic medicines for improving mental health. Peter H. Addy, PhD, LPC, LMHC, reveals how MDMA-assisted psychotherapy promotes post-traumatic growth in clients with treatment-resistant conditions.
Peter H Addy, PhD, LPC, LMHC, has studied psychedelic substances and states and consciousness for 15 years. He earned a PhD in clinical psychology studying transcendence, wholeness, and transformation and conducted one of the earliest studies of the atypical psychedelic plant Salvia divinorum in humans. He continued refining his research and clinical skills at Yale University where he studied Salvia and other atypical psychedelics and co-founded the Yale Psychedelic Science Group. He has completed postdoctoral training in substance use disorder treatment, participated in non-directive harm reduction and integration training at Burning Man, and traveled to Mexico to learn about indigenous use of psychedelic plants among the Mazatec people. He is currently a psychotherapist in private practice in Washington and Oregon.
Dr. Addy has presented internationally on a variety of subjects related to spirituality and transpersonal states, psychedelic science, and research methodology. Participants consistently regarded his talks as informative, accessible, and humorous. He has written numerous scientific articles, book chapters, and popular press articles on typical and atypical psychedelics, substance abuse, and spirituality.
Financial: Dr. Peter Addy maintains a private practice and has an employment relationship with the Synaptic Training Institute. He receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Peter Addy has no relevant non-financial relationships.